SG11202101547WA - Pharmaceutical composition for oral administration - Google Patents
Pharmaceutical composition for oral administrationInfo
- Publication number
- SG11202101547WA SG11202101547WA SG11202101547WA SG11202101547WA SG11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA SG 11202101547W A SG11202101547W A SG 11202101547WA
- Authority
- SG
- Singapore
- Prior art keywords
- pharmaceutical composition
- oral administration
- oral
- administration
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018163234 | 2018-08-31 | ||
PCT/JP2019/034051 WO2020045607A1 (en) | 2018-08-31 | 2019-08-30 | Pharmaceutical composition for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101547WA true SG11202101547WA (en) | 2021-03-30 |
Family
ID=69642788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101547WA SG11202101547WA (en) | 2018-08-31 | 2019-08-30 | Pharmaceutical composition for oral administration |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210346392A1 (en) |
EP (1) | EP3845230B1 (en) |
JP (1) | JP7355020B2 (en) |
KR (1) | KR20210052495A (en) |
CN (1) | CN112638390A (en) |
CA (1) | CA3108993C (en) |
ES (1) | ES2958158T3 (en) |
MX (1) | MX2021002385A (en) |
PH (1) | PH12021550251A1 (en) |
PL (1) | PL3845230T3 (en) |
PT (1) | PT3845230T (en) |
SG (1) | SG11202101547WA (en) |
TW (1) | TW202023565A (en) |
WO (1) | WO2020045607A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022123701A1 (en) | 2020-12-09 | 2022-06-16 | 昭和電工マテリアルズ株式会社 | Packed negative electrode material, negative electrode material transportation method, negative electrode material storage container, and negative electrode material storage method |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58134033A (en) | 1982-02-02 | 1983-08-10 | Fujisawa Pharmaceut Co Ltd | Drug composition |
KR101422301B1 (en) * | 2006-04-26 | 2014-07-30 | 에프. 호프만-라 로슈 아게 | Pharmaceutical compounds |
BR112016007588A2 (en) * | 2013-10-17 | 2017-09-12 | Bayer Pharma AG | pharmaceutical dosage forms comprising 1- [6- (morpholin-4-yl) pyrimidin-4-yl] -4- (1h-1,2,3-triazol-1-yl) -1h-pyrazol-5-olate sodium |
TWI648281B (en) * | 2013-10-17 | 2019-01-21 | 日商安斯泰來製藥股份有限公司 | Sulfur-containing bicyclic compound |
-
2019
- 2019-08-30 KR KR1020217009054A patent/KR20210052495A/en active Search and Examination
- 2019-08-30 EP EP19855123.6A patent/EP3845230B1/en active Active
- 2019-08-30 WO PCT/JP2019/034051 patent/WO2020045607A1/en active Application Filing
- 2019-08-30 CA CA3108993A patent/CA3108993C/en active Active
- 2019-08-30 US US17/272,028 patent/US20210346392A1/en active Pending
- 2019-08-30 SG SG11202101547WA patent/SG11202101547WA/en unknown
- 2019-08-30 PL PL19855123.6T patent/PL3845230T3/en unknown
- 2019-08-30 PT PT198551236T patent/PT3845230T/en unknown
- 2019-08-30 MX MX2021002385A patent/MX2021002385A/en unknown
- 2019-08-30 ES ES19855123T patent/ES2958158T3/en active Active
- 2019-08-30 JP JP2020539609A patent/JP7355020B2/en active Active
- 2019-08-30 CN CN201980055874.8A patent/CN112638390A/en active Pending
- 2019-08-30 TW TW108131175A patent/TW202023565A/en unknown
-
2021
- 2021-02-02 PH PH12021550251A patent/PH12021550251A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3108993A1 (en) | 2020-03-05 |
CN112638390A (en) | 2021-04-09 |
PL3845230T3 (en) | 2023-12-27 |
JPWO2020045607A1 (en) | 2021-08-12 |
EP3845230B1 (en) | 2023-07-12 |
JP7355020B2 (en) | 2023-10-03 |
WO2020045607A1 (en) | 2020-03-05 |
EP3845230A1 (en) | 2021-07-07 |
CA3108993C (en) | 2023-10-17 |
MX2021002385A (en) | 2021-04-29 |
EP3845230A4 (en) | 2022-06-01 |
PT3845230T (en) | 2023-09-27 |
TW202023565A (en) | 2020-07-01 |
ES2958158T3 (en) | 2024-02-02 |
US20210346392A1 (en) | 2021-11-11 |
KR20210052495A (en) | 2021-05-10 |
PH12021550251A1 (en) | 2021-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258464A (en) | Pharmaceutical formulations for the oral delivery of peptide drugs | |
IL270812A (en) | Solid compositions for oral administration | |
HUP1700253A1 (en) | Solid preparations for oral administration | |
HK1248544A1 (en) | Stable pharmaceutical composition for oral administration | |
EP3784214A4 (en) | Liquid oral pharmaceutical dosage form | |
IL282163A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
IL290469A (en) | Oral pharmaceutical composition | |
HK1245646A1 (en) | Pharmaceutical composition for oral administration | |
GB2591396B (en) | Pharmaceutical suspension for oral dosage | |
SG11202101547WA (en) | Pharmaceutical composition for oral administration | |
IL282842A (en) | Pharmaceutical formulations for subcutaneous administration | |
EP3880171C0 (en) | Ibuprofen-containing oral pharmaceutical formulation | |
FI3908321T3 (en) | Pharmaceutical composition | |
PT3650024T (en) | Pharmaceutical composition for nasal administration | |
HK1232144A1 (en) | Pharmaceutical composition for oral administration | |
GB2561723B (en) | A composition for oral administration | |
GB201908003D0 (en) | Pharmaceutical composition |